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Background: In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated
significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal
women with hormone receptor-positive (HR+) advanced breast cancer. We report on the incidence, time course, severity,
and resolution of treatment-emergent adverse events (AEs) as well as incidence of dose modifications during the
extended follow-up of this study.
Patients and methods: Patients were randomized (2:1) to receive EVE 10 mg/day or placebo (PBO), with open-label
EXE 25 mg/day (n = 724). The primary end point was progression-free survival. Secondary end points included overall
survival, objective response rate, and safety. Safety evaluations included recording of AEs, laboratory values, dose inter-
ruptions/adjustments, and study drug discontinuations.
Results: The safety population comprised 720 patients (EVE + EXE, 482; PBO + EXE, 238). The median follow-up was
18 months. Class-effect toxicities, including stomatitis, pneumonitis, and hyperglycemia, were generally of mild or moder-
ate severity and occurred relatively early after treatment initiation (except pneumonitis); incidence tapered off thereafter.
EVE dose reduction and interruption (360 and 705 events, respectively) required for AE management were independent
of patient age. The median duration of dose interruption was 7 days. Discontinuation of both study drugs because of AEs
was higher with EVE + EXE (9%) versus PBO + EXE (3%).
Conclusions: Most EVE-associated AEs occur soon after initiation of therapy, are typically of mild or moderate severity,
and are generally manageable with dose reduction and interruption. Discontinuation due to toxicity was uncommon.
Understanding the time course of class-effect AEs will help inform preventive and monitoring strategies as well as patient
education.
Trial registration number: NCT00863655.
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introduction
Non-steroidal aromatase inhibitors (NSAIs) such as anastrozole
and letrozole are highly effective therapies for postmenopausal
women with hormone receptor-positive (HR+) advanced breast
cancer (BC) [1, 2], but disease progression occurs even after
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initial response [3]. Hyperactivation of the phosphatidylinositol
3-kinase/protein kinase B/mammalian target of rapamycin
(PI3K/AKT/mTOR) signaling pathway and crosstalk between
the mTOR and estrogen receptor pathways are implicated in BC
progression and endocrine therapy resistance [4].
Everolimus (EVE; Afinitor®, Novartis) is an oral mTOR in-
hibitor that enhanced endocrine sensitivity [5] and produced
synergistic antiproliferative and apoptotic activity when com-
bined with letrozole [6]. In the randomized, phase 3 BOLERO-2
trial in postmenopausal women with HR+ advanced BC who
progressed on/after NSAIs, EVE + exemestane (EXE) signifi-
cantly improved progression-free survival (PFS) compared with
placebo (PBO) + EXE [hazard ratio (HR) = 0.43, P < 0.001 by
local investigator assessment; HR = 0.36, P < 0.001 by central as-
sessment] [3]. Adverse events (AEs) were consistent with the
known safety profile of EVE. These results supported the recent
marketing authorization of EVE + EXE in the United States,
Europe, and several other countries for treating postmenopausal
women with HR+ advanced BC that recurred or progressed on
letrozole or anastrozole [7, 8].
Treatment-emergent AEs reported with EVE included stoma-
titis, rash, diarrhea, fatigue, hyperglycemia, hyperlipidemia,
infections, and, less commonly, non-infectious pneumonitis [3,
9–11]. Hyperglycemia and dyslipidemia are of special interest in
postmenopausal women with BC who might be at risk for age-
related metabolic abnormalities. This report evaluates the safety
of EVE + EXE in postmenopausal women in BOLERO-2 based
on the median follow-up of 18 months. The incidences of clinic-
ally important toxicities associated with EVE, their time course
of onset and resolution, as well as the incidences of dose reduc-
tions, delays, and discontinuations are described.
methods
eligibility criteria
Inclusion and exclusion criteria have been previously described [3] and are
presented in the supplementary material, available at Annals of Oncology
online.
study design
In this international, multicenter, double-blind study (NCT00863655),
patients were randomized in a 2:1 ratio to EVE (10 mg/day) or matching
PBO plus open-label EXE (25 mg/day). Randomization was stratified by
documented sensitivity to previous hormonal therapy and the presence of
visceral metastasis [3].
The primary end point was PFS; secondary end points included objective
response rate, overall survival, and safety. This analysis evaluated safety;
results of other end points are presented elsewhere [3, 12, 13].
safety evaluations and dose modifications
Safety assessments included AEs, serious AEs (SAEs), vital signs, and clinical
laboratory tests (hematology, serum chemistry, serum lipid profile, and urin-
alysis) at baseline and every 6 weeks thereafter. AEs were graded according
to the National Cancer Institute Common Terminology Criteria for Adverse
Events, version 3.0 [14].
For toxicity-related treatment interruptions, the initial dose was to be
resumed after the event(s) resolved to grade ≤1 (Table 1) [7]. Exceptions
included pneumonitis (grade ≥2), stomatitis (grade ≥3), and any grade 4
toxicity, wherein treatment was resumed at a lower dose. Dose reductions
were not required for hyperglycemia, hyperlipidemia, and/or hypertriglycer-
idemia. EVE dose re-escalation to starting dose was permitted based on
safety findings. A maximum of 2 dose-level reductions were allowed (−1
dose level: 5 mg/day; −2 dose levels: 5 mg every other day). Treatment was
permanently discontinued in patients requiring reductions beyond 2 dose
levels or dose interruptions lasting more than 4 weeks. Patients were fol-
lowed for onset of new SAEs for 28 days after the last dose.
statistical analysis
The analysis cut-off date was 15 December 2011 (median follow-up, 18
months). The safety population included all patients who received ≥1 dose
of study treatment and had ≥1 postbaseline safety evaluation. AEs were sum-
marized using percentages and frequency counts. The Kaplan–Meier
method was used to evaluate time-to-onset and time-to-resolution of AEs of
clinical interest (presented by grouped terms as outlined in supplementary
material, available at Annals of Oncology online). Statistical analyses were
conducted using SAS® version 9.3 (SAS Institute, Cary, NC).
Table 1. Everolimus dose modifications for non-hematologic adverse events (excluding metabolic events)
Severity Everolimus dose adjustmenta Management recommendations
Grade 1 No dose adjustment required Initiate appropriate medical therapy and monitor
Grade 2 • If toxicity is tolerable, no dose adjustment required
• If toxicity becomes intolerable, temporary dose interruption until
recovery to grade ≤1. Reinitiate EVE at same doseb
• If toxicity recurs at grade 2, interrupt EVE until recovery to grade ≤1.
Reinitiate EVE at a lower dose
Initiate appropriate medical therapy and monitor
Grade 3 • Temporary dose interruption until recovery to grade ≤1
• Consider reinitiating EVE at a lower dose
• If toxicity recurs at grade 3, consider discontinuation
Initiate appropriate medical therapy and monitor
Grade 4 Discontinue EVE Treat with appropriate medical therapy
AE, adverse event; EVE, everolimus.
aIf dose reduction is required, the suggested dose is ∼50% lower than the dose previously administered.
bFor non-infectious pneumonitis, everolimus should be reinitiated at a lower dose level (everolimus package insert, 2012).
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results
patient population
A total of 724 patients were randomized. The safety population
comprised 720 patients: 482 in the EVE + EXE arm and 238 in
the PBO + EXE arm. The treatment arms were balanced for
demographics, disease characteristics, and previous treatment
[13]. The median age was 61 years (range, 28–93 years), and
most patients were Caucasian (75%) or Asian (20%).
patient disposition and exposure
In the safety population, the median duration of treatment ex-
posure was longer in the EVE + EXE arm than in the
PBO + EXE arm at 23.9 and 29.5 weeks for EVE and EXE, re-
spectively, versus 13.4 and 14.1 weeks for PBO and EXE, re-
spectively. The median dose intensity was 8.6 mg/day for EVE
(details are presented in supplementary materials, available at
Annals of Oncology online).
overall AE profile
AEs were experienced by all patients in the EVE + EXE arm and
by 91% in the PBO + EXE arm (supplementary Figure S1, avail-
able at Annals of Oncology online) [13]. The most frequently
reported all-grade AEs (in at least one-third of patients) in the
EVE + EXE arm included stomatitis, rash, fatigue, and diarrhea.
Most events were grade 1 or 2. The most common grade 3 or 4
AEs in the EVE + EXE arm were stomatitis, anemia, and hyper-
glycemia. Non-infectious pneumonitis occurred only in patients
receiving EVE + EXE; most events were low grade, with 3%
grade 3 and <1% grade 4 events. Hot flushes were reported at a
lower frequency in the EVE + EXE arm (5.6%) than in the
PBO + EXE arm (14.3%). These findings are consistent with
those from the other two EVE BC trials [15, 16].
frequency and time course of AEs of interest
stomatitis. The frequency of all-grade stomatitis and related
events was higher in the EVE + EXE arm than in the
PBO + EXE arm (67% versus 12%, respectively). Grade 3 events
occurred in 8% and <1% of patients, respectively; no grade 4
events were observed.
In the EVE + EXE arm, more than one-third of all stomatitis
events (grade ≥2) were reported in the first 2 weeks (cumulative
risk, 14%). The cumulative risks of stomatitis at 6 and 48 weeks
were 26% and 37%, respectively, for EVE + EXE versus 3% for
PBO + EXE (Figure 1A). Among 39 patients with grade ≥3 sto-
matitis in the EVE + EXE arm, 97% experienced resolution to
grade ≤1 following dose interruption/reduction after a median
of 3.1 weeks (Table 2), and 82% had complete resolution after a
median of 7.4 weeks. In the PBO + EXE arm, the median time
to resolution from grade 3 to grade ≤1 was 2.6 weeks (time to
complete resolution was not assessable; one of two patients had
complete resolution).
pneumonitis. Overall, 20% of patients in the EVE + EXE arm
had non-infectious pneumonitis or related events, compared
with <1% in the PBO + EXE arm [13]. Grade 3 events occurred
in 4% of patients and one grade 4 event was reported.
The time course for pneumonitis differed from stomatitis, with
few early events and no appreciable plateau. Approximately
one-quarter of events (grade ≥2) occurred within the first 12
weeks (cumulative risk, 5%). Cumulative risks of pneumonitis
(grade ≥2) in the EVE + EXE arm were 10% and 16% at 24 and
48 weeks, respectively (Figure 1B). Among patients with grade 3
pneumonitis in the EVE + EXE arm, 80% experienced reso-
lution to grade ≤1, typically following dose interruption/reduc-
tion, after a median of 3.8 weeks (Table 2). Complete resolution
of grade ≥3 pneumonitis was reported in 75% of patients, after a
median of 5.4 weeks.
hyperglycemia. At study entry, 9% of patients in the
EVE + EXE arm and 10% in the PBO + EXE arm had diabetes
mellitus or impaired glucose tolerance. During the study, more
patients in the EVE + EXE arm (11%) developed grade ≥2
hyperglycemia or new-onset diabetes mellitus compared with
those receiving PBO + EXE (2%). The incidence of all-grade
hyperglycemia and new-onset diabetes mellitus was higher in
the EVE + EXE arm than in the PBO + EXE arm (16% versus
3%, respectively), with grade 3 or 4 events occurring in 6% and
1% of patients, respectively [13].
Approximately half of all hyperglycemia/new-onset diabetes
mellitus events (grade ≥2) occurred within the first 6 weeks (cu-
mulative risk, 7%). The cumulative risk at 48 weeks was 13% in
the EVE + EXE arm compared with 3% in the PBO + EXE arm
(Figure 1C). Among patients with grade 3 or 4 events in the
EVE + EXE arm, 46% experienced resolution to grade ≤1 after a
median of 29.1 weeks (Table 2).
fatigue. Fatigue was reported in 37% of patients in the
EVE + EXE arm compared with 27% in the PBO + EXE arm
(Table 2) [13]. Grade 3 or 4 events were more frequent in the
experimental arm (grade 3, 4% versus 1%; grade 4, <1% versus
0%, respectively).
More than one-third of fatigue events (grade ≥2) occurred
within 6 weeks of treatment initiation (cumulative risk, 11%).
The cumulative risk at 48 weeks was 28% in the EVE + EXE arm
and 20% in the PBO + EXE arm (Figure 1D). Among patients
with grade 3 or 4 fatigue, 72% in the EVE + EXE arm experi-
enced resolution, usually following dose interruption/reduction,
to grade ≤1 after a median of 8.0 weeks (Table 2). Complete
resolution was reported in 56% of EVE + EXE-treated patients
after a median of 18.7 weeks. None of the patients in the
PBO + EXE arm with grade 3 or 4 fatigue achieved complete
resolution.
hyperlipidemia. Patients treated with EVE + EXE (14%) had a
higher incidence of hyperlipidemia compared with those treated
with PBO + EXE (2%). The combined incidence of grade 3 or 4
hyperlipidemia was 1% in the EVE + EXE arm and 0% in the
PBO + EXE arm. The cumulative risk of hyperlipidemia (grade
≥2) at 48 weeks was 8% in the EVE + EXE arm.
dose interruptions and reductions/adjustments
Dose interruptions/reductions were required in 301 EVE
patients (62%) and in 28 PBO patients (12%). The median dur-
ation of dose interruptions/reductions was higher with EVE
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(11 days) than with PBO (1 day) or EXE (1–2 days) (Table 3).
Among 1065 instances of EVE dose interruptions/reductions,
463 (44%) resolved with resumption of full dosing; 352 of these
events (76%) resolved within 2 weeks.
The most common AEs leading to dose interruptions/reduc-
tions (≥3% of patients) in the EVE + EXE arm (by preferred
terms) were stomatitis (23.7%), pneumonitis (7.5%), alanine
aminotransferase increase (4.6%), aspartate aminotransferase
increase (4.4%), dyspnea (3.7%), blood creatinine increase
(3.3%), and fatigue (3.1%). The difference between the actual in-
cidence of dose modifications because of pneumonitis (7.5%)
versus what may have been expected based on the proportion of
patients with grade ≥2 pneumonitis events (8.9%) may be
attributed to the fact that some patients discontinued treatment
for pneumonitis, based on investigator discretion, without dose
modification. No predominant AE led to dose interruptions/
reductions in the PBO + EXE arm. Dose interruptions/reduc-
tions because of AEs were not substantially affected by patient
age or last prior therapy (supplementary Table S1, available at
Annals of Oncology online).
In the EVE + EXE arm, 163 patients (34%) required a dose re-
duction to 5 mg EVE/day (1 dose-level reduction). The median
time to first dose reduction was 55 days (range, 6–483 days) in
the overall population. The median time to first dose reduction
in younger patients [<65 years: 52 days (range, 11–483 days)]
was comparable with that observed in elderly patients [≥65
years: 60 days (range, 6–440 days)]. Thirteen patients re-esca-
lated to the full EVE dose after being dose-reduced because of
an AE (details provided in supplementary material, available at
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Figure 1. Cumulative risk estimates for initial onset of grade ≥2 (A) stomatitis, (B) pneumonitis, (C) hyperglycemia/new-onset diabetes mellitus, and
(D) fatigue. EVE, everolimus; EXE, exemestane; PBO, placebo.
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discontinuations because of AEs
The rates of treatment discontinuation because of treatment-
emergent AEs were higher in the EVE + EXE arm (n = 485; 26%
for EVE and 9% for EXE) compared with the PBO + EXE arm
(n = 239; 5% for PBO and 3% for EXE). The most common AEs
leading to treatment discontinuation in the EVE + EXE arm
included pneumonitis (5.6%), stomatitis (2.7%), dyspnea
(2.3%), and fatigue (1.9%) (Table 4).
discussion
In BOLERO-2, the EVE + EXE combination significantly
improved PFS compared with PBO + EXE in postmenopausal
women recurring or progressing on NSAIs; toxicity was well-
managed by dose interruption and reduction [3]. In the current
analyses, representing 10 months of additional follow-up, no
new or unexpected safety signals were observed with
EVE + EXE, and the AE profile was consistent with earlier
interim reports and previous reports of EVE in BC and other
oncology settings [3, 9–11]. Class-effect AEs (except pneumon-
itis) had a relatively short time to onset, and the incidence
tapered off thereafter. Grade 3 or 4 AEs occurred at a low rate,
and most resolved to grade ≤1 fairly rapidly. Management
recommendations for EVE-related AEs included dose interrup-
tions/reductions and facilitated continued treatment in most
cases (perspectives on current guidelines for managing AEs of
interest are presented in the supplementary material, available at
Annals of Oncology online).
The incidences of some mTOR inhibitor class-effect AEs,
such as stomatitis, rash, and non-infectious pneumonitis, were
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Caucasian patients in BOLERO-2 [17]. This was also observed
with EVE in patients with metastatic renal cell carcinoma
(RECORD-1) [18]. However, the incidences of higher-grade
AEs requiring dose interruption/adjustment in BOLERO-2 were
similar in Asians and Caucasians, supporting generally similar
efficacy and tolerability of EVE among different racial sub-
groups. Consistent with previous clinical studies evaluating
mTOR inhibitors versus endocrine agents, 12% of patients in
the PBO + EXE arm experienced stomatitis or related events.
This may reflect general vigilance by trial investigators toward
class-effect AEs with the drugs under study [15, 16, 19].
Notably, the incidence and severity of AEs reported in this study
were consistent with historical data, and the double-blinded trial
design precluded bias in AE reporting. Dose interruptions/
adjustments were also not affected by patient age, last prior
chemotherapy, or endocrine therapy. Older patients did not
Table 3. Incidence and median duration of dose reduction and interruption events and time to resumption of full study dose
EVE EXE PBO EXE
Duration of dose reductions/interruptions
Number of dose reductions/interruptions (n) 1065 224 114 65
Median duration (days) (range) 11 (1–672) 2 (1–47) 1 (1–131) 1 (1–20)
Number of dose reductions (n) 360 1 9 0
Median duration (days) (range) 29 (1–672) 7 (7–7) 20 (2–131) 0
Number of dose interruptions (n) 705 223 105 68
Median duration (days) (range) 7 (1–41) 2 (1–47) 1 (1–26) 1 (1–20)
Time to resumption of full drug dose
≤1 week [n (%)] 219 (47) 154 (69) 88 (85) 59 (87)
>1 and ≤2 weeks [n (%)] 133 (29) 44 (20) 9 (9) 7 (10)
>2 and ≤3 weeks [n (%)] 55 (12) 14 (6) 4 (4) 2 (3)
>3 weeks [n (%)] 56 (12) 11 (5) 2 (2) 0
Median time to resumption of full dosea (days) (range) 8 (2–333) 3 (2–48) 2 (2–27) 2 (2–21)
EVE, everolimus; EXE, exemestane; PBO, placebo.
aIn patients who were able to resume study drug.
Table 2. Time to adverse event resolution from grade 3/4 to grade ≤1
Adverse event EVE + EXE (n = 482) PBO + EXE (n = 238)
Stomatitis and related events n = 39 n = 2
Proportion resolveda 97% 100%
Median time to resolution (week) (95% CI) 3.1 (1.9–5.3) 2.6 (1.0–4.1)
Fatigue n = 32 n = 4
Proportion resolveda 72% 25%
Median time to resolution (week) (95% CI) 8.0 (2.7–18.7) NA (14.0–NA)
Non-infectious pneumonitis n = 20 n = 0
Proportion resolveda 80% 0
Median time to resolution (week) (95% CI) 3.8 (1.3–7.1)
Hyperglycemia and new onset of DM n = 28 n = 2
Proportion resolveda 46% 50%
Median time to resolution (week) (95% CI) 29.1 (10.1–NA) NA (3.0–NA)
Hyperlipidemia n = 4 n = 0
Proportion resolveda 25% 0
Median time to resolution (week) (95% CI) NA (19.3–NA)
Infections and infestations n = 32 n = 4
Proportion resolveda 84% 100%
Median time to resolution (week) (95% CI) 3.0 (1.0–18.0) 1.6 (0.3–2.9)
CI, confidence interval; DM, diabetes mellitus; EVE, everolimus; EXE, exemestane; NA, not assessable (because of very low event rates); PBO, placebo.
aNumber of patients with grade 3/4 adverse events that resolved to grade ≤1. The denominator of the percentage is the total for that preferred term. For
example, for stomatitis and related events with EVE therapy, the proportion of patients whose adverse event resolved to grade ≤1 was 38/
39 × 100 = 97%.
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experience significantly different rates of AEs necessitating dose
interruptions/adjustments, despite a potentially higher preva-
lence of comorbidities and concomitant medications. The dur-
ation of dose interruptions/reductions was relatively short, and
most patients who resumed the full 10 mg EVE dose did so
within 2 weeks, thereby maintaining dose intensity.
Despite EVE dose interruptions/reductions, a significant im-
provement in efficacy was seen, supporting the timely manage-
ment of AEs. Dose-modification guidelines, including treatment
discontinuation, have been established for managing non-
hematologic AEs during EVE therapy (Table 1) [7]. Careful
application of established AE management recommendations as
well as patient education about the time course of AE onset and
resolution may improve tolerability and treatment adherence.
Given the potential for prolonged use of EVE in patients with
HR+, HER2-negative advanced BC, optimal patient safety and
benefit from this therapy are contingent upon clinicians’ ability
to recognize, monitor, and effectively manage class-effect toxici-
ties associated with EVE therapy.
In conclusion, these results expand our understanding of the
benefits, tolerability, and risks of EVE + EXE in postmenopausal
women with HR+ advanced BC progressing after letrozole or
anastrozole and provide important data critical for management
of toxicity. The AE profile of EVE does not overlap with existing
systemic therapies. Most EVE-emergent AEs were mild or mod-
erate and were manageable. Understanding the time course of
AEs will allow appropriate patient education, inform frequency
of monitoring, and aid in the development of prevention and
treatment strategies; it is particularly important given the clinic-
al benefit obtained from adding EVE to EXE and the differential
toxicities associated with this targeted agent.
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